Multiple Myeloma and Minimal Residual Disease research hub

PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR).

This study looks at whether a drug called DARZALEX can help people with multiple myeloma whose cancer is showing early signs of coming back. It compares giving DARZALEX early versus watching and waiting to see if the cancer grows.